Adagene Inc
$ 3.32
-7.26%
05 Jun - close price
- Market Cap 236,540,000 USD
- Current Price $ 3.32
- High / Low $ 3.56 / 3.16
- Stock P/E N/A
- Book Value 0.75
- EPS -0.37
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.34 %
- 52 Week High 4.75
- 52 Week Low 1.30
About
Adagene Inc., a clinical-stage biopharmaceutical company, is dedicated to the research, development, and production of monoclonal antibody drugs for cancer. The company is headquartered in Suzhou, China.
Analyst Target Price
$9.40
Quarterly Earnings
| Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-01 | 2025-12-03 | 2025-08-12 | 2025-05-28 | 2025-03-24 | 2024-11-27 | 2024-07-25 | 2024-05-29 | 2024-03-29 | 2023-11-29 | 2023-08-31 | 2023-05-31 |
| Reported EPS | 0 | 0 | -0.23 | -0.17 | -0.29 | 0 | -0.285 | 0 | -0.27 | -0.42 | -1.48 | -0.38 |
| Estimated EPS | -0.21 | -0.18 | -0.33 | -0.17 | -0.47 | 0 | -0.26 | 0 | -0.27 | -0.42 | -0.93 | -0.38 |
| Surprise | 0.21 | 0.18 | 0.1 | 0 | 0.18 | 0 | -0.025 | 0 | 0 | 0 | -0.55 | 0 |
| Surprise Percentage | 100% | 100% | 30.303% | 0% | 38.2979% | None% | -9.6154% | None% | 0% | 0% | -59.1398% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ADAG
2026-06-05 15:39:14
Adagene Inc. (ADAG) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive shift in its earnings outlook. This upgrade is driven by an upward trend in earnings estimates, which the Zacks system identifies as a powerful force influencing stock prices. The article suggests that this improvement in Adagene's underlying business could lead to a favorable impact on its stock price for investors.
2026-06-02 13:40:00
Adagene Inc. Sponsored ADR (ADAG) has significantly outperformed the Medical sector and its specific industry, Medical - Biomedical and Genetics, this year with a 100% year-to-date return. This strong performance is backed by a Zacks Rank of #2 (Buy) and a 37.3% increase in full-year earnings estimates. Contineum Therapeutics, Inc. (CTNM) is another Medical stock showing strong performance within the sector.
2026-06-01 15:40:53
The provided content is merely "MSN", which is insufficient to generate a summary. Therefore, no summary can be created based on the given information.
2026-05-21 21:09:14
This article lists 12 healthcare stocks that experienced significant movement in Thursday's after-market session. It highlights both gainers, such as Akari Therapeutics and BioNTech, and losers, including NervGen Pharma and Adagene, along with their respective percentage changes and market capitalizations.
2026-05-20 16:39:35
Adagene highlighted its ADG126 antibody program, a masked anti-CTLA-4 antibody, emphasizing its enhanced therapeutic index compared to first-generation CTLA-4 therapies. The company is advancing ADG126 in a randomized Phase 2 trial for late-line microsatellite-stable colorectal cancer, particularly in patients without liver metastases, showing promising dose-dependent response rates and an improved safety profile. Adagene has also secured collaborations with Incyte and Sanofi to further explore ADG126 in combination therapies and recently raised $70 million to fund its clinical development.
2026-05-20 15:38:47
Adagene's Chief Strategy Officer Mickael Chane-Du detailed the clinical strategy for ADG126 (muzastotug), a masked anti-CTLA-4 antibody, emphasizing its improved therapeutic index in colorectal cancer. The company is advancing a randomized Phase 2 trial for ADG126 in combination with pembrolizumab for late-line MSS-CRC and is also engaged in collaborations with Incyte and Sanofi to explore further development options. Adagene recently secured $70 million in financing, extending its operational runway into the second half of 2028.
